- Home
- SNTG vs JAGX Comparison
SNTG vs JAGX Comparison
Compare SNTG & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNTG | JAGX |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 5.6M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SNTG | JAGX |
|---|---|---|
| Price | $1.99 | $0.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 9.8K | ★ 486.0K |
| Earning Date | 12-19-2025 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,689,000.00 |
| Revenue This Year | N/A | $22.41 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.75 |
| 52 Week Low | $1.43 | $0.20 |
| 52 Week High | $12.70 | $15.48 |
Technical Indicators
Market Signals| Indicator | SNTG | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 51.03 | 34.72 |
| Support Level | $1.97 | N/A |
| Resistance Level | $2.11 | $0.69 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 52.00 | 1.46 |
Price Performance
Historical ComparisonAbout SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.